Form 8-K - Current report:
SEC Accession No. 0001193125-25-032826
Filing Date
2025-02-24
Accepted
2025-02-24 08:17:33
Documents
13
Period of Report
2025-02-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d918567d8k.htm   iXBRL 8-K 23871
  Complete submission text file 0001193125-25-032826.txt   145811

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA avir-20250220.xsd EX-101.SCH 2859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20250220_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20250220_pre.xml EX-101.PRE 11267
15 EXTRACTED XBRL INSTANCE DOCUMENT d918567d8k_htm.xml XML 3638
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 25654312
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)